Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 7.9% - What's Next?
Stoke Therapeutics (NASDAQ:STOK) saw its stock price drop by 7.9% to $30.42 after reporting an EPS loss of $0.93, missing consensus estimates despite exceeding revenue expectations. Despite the recent dip and insider sales, analysts maintain a "Moderate Buy" rating with an average target price of $43.00, suggesting significant upside. The company is developing STK-001 for Dravet syndrome using its TANGO platform, and institutional investors have been adjusting their positions.
Bank of America Corp DE Buys 336,931 Shares of Stoke Therapeutics, Inc. $STOK
Bank of America Corp DE significantly increased its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 163.4% in the first quarter, now owning 543,095 shares valued at $17.68 million. Other institutional investors like RTW Investments LP and Redmile Group LLC also boosted their holdings. Despite recent insider selling, the stock currently holds a "Moderate Buy" consensus rating from analysts with a target price of $43.00.
Is Strong EMPEROR Trial Enrollment and Retention Altering The Investment Case For Stoke Therapeutics (STOK)?
Stoke Therapeutics' Phase III EMPEROR trial for zorevunersen in Dravet syndrome has exceeded its 150-patient enrollment goal, reaching 162 patients with no discontinuations, which is expected to strengthen confidence as the company approaches regulatory milestones. This positive development could influence the investment narrative, with plans to begin a rolling FDA New Drug Application in Q1 2027 and complete it by Q3 2027. Despite ongoing losses, the strong trial execution is a key near-term catalyst, though the biggest risk remains whether full Phase III data will confirm earlier positive results.
Stoke therapeutics CMO Barry Ticho sells $152k in stock
Stoke Therapeutics' Chief Medical Officer, Barry Ticho, sold shares worth $152,689 on August 18, 2026, to cover tax liabilities from restricted stock unit vesting, following his acquisition of 10,000 shares from performance stock units. This transaction occurred amidst recent financial disclosures by Stoke Therapeutics, including a wider-than-expected Q2 2026 loss but significant revenue beat, and progress in its Dravet syndrome program, zorevunersen.
Stoke Therapeutics general counsel Allan sells $91,639 in stock
Jonathan Allan, General Counsel at Stoke Therapeutics, sold 2,861 shares of company stock worth $91,639 to cover tax liabilities related to restricted stock unit vesting. This sale occurred on August 18, 2026, after he acquired 6,000 shares from vested performance stock units on August 14, 2026. The stock is performing well, and the company recently reported strong revenue growth, attributed to its lead Dravet syndrome program, zorevunersen, despite a wider-than-expected loss.
Stoke Therapeutics’ director Kaye sells $402,528 in shares
Edward M. Kaye MD, a director at Stoke Therapeutics, Inc. (NASDAQ:STOK), recently sold shares worth $402,528 to cover tax liabilities related to restricted stock unit vesting. These transactions occurred on August 18, 2026, following his acquisition of 26,250 shares through performance stock units on August 14, 2026. Despite the stock's 74% return over the past year, InvestingPro analysis suggests it is slightly overvalued as the company is not yet profitable.
Stoke therapeutics CMO Barry Ticho sells $152k in stock By Investing.com
Barry Ticho, Chief Medical Officer at Stoke Therapeutics (NASDAQ:STOK), sold $152,689 worth of company stock on August 18, 2026, to cover tax withholding liabilities from vested restricted stock units. This sale occurred after he acquired 10,000 shares through vested performance stock units on August 14, 2026. Despite the stock potentially being overvalued according to InvestingPro analysis, it has seen a 74% return over the past year.
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 2,861 Shares
Stoke Therapeutics' General Counsel, Jonathan Allan, sold 2,861 shares of the company's stock for approximately $91,638 to cover tax withholdings from vested equity awards, reducing his holdings by 11.88%. Despite missing earnings per share estimates, the company's revenue exceeded expectations. Analysts maintain a "Moderate Buy" rating with an average price target of $43, significantly higher than the current stock price.
Is Stoke Therapeutics (STOK) A Bargain On Its EMPEROR Trial Enrollment Milestone?
Stoke Therapeutics (STOK) is gaining attention after its Phase III EMPEROR trial for Dravet syndrome enrolled 162 patients, exceeding its 150-patient target without discontinuations. The stock has seen significant returns over the past year, and analysts currently peg its fair value at $45.10, suggesting it is 28.7% undervalued compared to its current share price of $32.14. However, potential trial underperformance and future pricing decisions for zorevunersen remain key risks.
Edward Md Kaye Sells 12,567 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock
Director Edward Md Kaye sold 12,567 shares of Stoke Therapeutics (NASDAQ:STOK) stock for approximately $402,521 to cover tax withholding obligations from vested equity awards, reducing his direct ownership by 9.16%. The company reported a quarterly loss of $0.93 per share, missing consensus estimates, but revenue of $9.32 million exceeded expectations. Despite unprofitability, analysts maintain a "Moderate Buy" rating with an average price target of $43.00.
Is Stoke Therapeutics (STOK) A Bargain On Its EMPEROR Trial Enrollment Milestone?
Stoke Therapeutics (STOK) has garnered attention after its Phase III EMPEROR trial for Dravet syndrome exceeded its enrollment target, reaching 162 participants with no discontinuations. The stock has seen strong returns, and analysts project a fair value of $45.10, indicating it might be undervalued. Investors are advised to consider potential trial underperformance and pricing challenges as key risks.
Stoke Therapeutics (STOK) insider sale tied to tax withholding
Stoke Therapeutics (STOK) General Counsel & Corporate Secretary, Jonathan Allan, reported exercising 6,000 Performance Stock Units into common stock and subsequently selling 2,861 shares. These sales, conducted at weighted average prices of approximately $32.01 and $32.47 per share, were mandated by the issuer to cover tax withholding liabilities related to the vesting and settlement of restricted stock units. Allan's direct common stock holdings after these transactions total 21,225 shares.
Stoke Therapeutics (STOK) director share sale tied to taxes
Stoke Therapeutics director Edward M. Kaye, MD, exercised 26,250 performance stock units into common shares on August 14, 2026. He subsequently sold 12,567 shares on August 18, 2026, at weighted average prices of $32.01 and $32.47. These sales were mandated by the issuer to cover tax withholding liabilities related to equity vesting.
Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts
Stoke Therapeutics' Phase III EMPEROR study for zorevunersen in Dravet syndrome has exceeded its enrollment target, with 162 patients enrolled against a goal of 150, and remarkably, zero patient discontinuations. CEO Ian Smith highlighted the drug's tolerability and the trial's strong retention, attributing it partly to the availability of an open-label extension. The study's primary endpoint is seizure reduction, but it also assesses cognitive and behavioral changes, with regulatory submission for a New Drug Application anticipated to begin in Q1 2027.
Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts
Stoke Therapeutics announced that its Phase III EMPEROR study for zorevunersen in Dravet syndrome has surpassed its enrollment target with 162 patients and zero dropouts, attributing the high retention to the drug's tolerability and an open-label extension. The trial's primary endpoint is seizure reduction at week 28, with secondary measures including cognitive and behavioral changes. Stoke plans to begin a rolling New Drug Application submission in Q1 2027, with potential efficacy data for its ADOA treatment expected in H1 2027.
Stoke Therapeutics (STOK) gets 6.5% stake disclosure from Lynx1 Capital
Lynx1 Capital Management LP and Weston Nichols have disclosed a 6.5% beneficial ownership stake in Stoke Therapeutics (STOK), totaling 4,038,404 common shares. This ownership is based on 62,240,347 shares outstanding as of March 31, 2026, with the reporting persons holding shared voting and dispositive power. The shares are held by Lynx1 Master Fund LP and a managed account, with Lynx1 Fund receiving dividends and sale proceeds.
Trading Systems Reacting to (STOK) Volatility
The article analyzes Stoke Therapeutics Inc. (NASDAQ: STOK), noting a near-term neutral sentiment amidst mid and long-term strength, with an exceptional 61.2:1 risk-reward setup. It details three AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored for different risk profiles and provides multi-timeframe signal analysis. The report highlights positive sentiment prevailing and offers real-time signals and risk parameters.
Stoke Therapeutics (STOK): TD Bank, TD Securities disclose 4.9% equity stake
TD Bank and TD Securities Inc. have jointly reported a beneficial ownership of 4.9% of Stoke Therapeutics, Inc. (STOK) common stock, totaling 3,183,258 shares. The filing, a SCHEDULE 13G/A, indicates that TD Bank holds sole voting and dispositive power over 3,173,258 shares, while TD Securities Inc. has control over 10,000 shares. Both entities deny forming a group for the purpose of influencing Stoke Therapeutics.
Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript
Stoke Therapeutics announced the completion of enrollment for its Phase III EMPEROR study of zorevunersen, with 162 patients, targeting a Q3 2027 data readout and an early 2028 commercial launch. The company reported a strong financial position with $420 million pro forma cash, sufficient to fund operations through the potential U.S. launch. Additionally, Stoke is advancing its pipeline with STK-002 for ADOA and lead optimization for SYNGAP1-related disorders.
Is Stoke Therapeutics' (STOK) New Shelf Filing Reframing Its Path Through Mounting Operating Losses?
Stoke Therapeutics (STOK) reported a significant net loss of US$61.62 million in Q2 2026 and US$111.62 million for the first half of 2026, alongside a drop in sales. The company also filed a US$57.72 million shelf registration for 2,000,000 common shares, signaling potential future dilution to fund its clinical programs. These developments suggest a re-evaluation of Stoke's investment narrative, emphasizing its dependence on clinical progress rather than current earnings and highlighting increased funding risk.
Is Stoke Therapeutics' (STOK) New Shelf Filing Reframing Its Path Through Mounting Operating Losses?
Stoke Therapeutics (STOK) reported a significant net loss of US$61.62 million in Q2 2026 and filed a US$57.72 million shelf registration for 2,000,000 common shares. These developments, coupled with declining sales, raise concerns about operating pressure and potential shareholder dilution, despite optimistic long-term forecasts for its lead drug, zorevunersen. The company's investment narrative is heavily reliant on clinical and regulatory progress, and the new shelf filing suggests that future funding for its EMPEROR Phase III trial might involve further equity issuance.
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Stoke Therapeutics announced that CEO Ian F. Smith will present at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, at 3:00 p.m. ET. The biotechnology company focuses on RNA medicine to restore protein expression, with its lead investigational medicine, zorevunersen, in development for Dravet syndrome. A live webcast of the presentation will be available on Stoke’s website.
Stoke Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:STOK) 2026-08-07
Stoke Therapeutics, Inc. (NASDAQ:STOK) released its Q2 2026 earnings call presentation on August 7, 2026. The company reported an EPS of -$0.93, missing estimates by $0.15, and revenue of $9.33M, which beat expectations by $4.24M despite a 32.51% year-over-year decrease. The presentation provides detailed financial insights for investors.
Analysts Have Made A Financial Statement On Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Second-Quarter Report
Stoke Therapeutics (NASDAQ:STOK) saw an 8.3% share price increase after reporting Q2 revenues of US$9.3m, surpassing expectations. However, statutory losses were higher than anticipated at US$0.93 per share. Analysts have since raised revenue estimates for 2026 to US$30.2m but also increased loss per share forecasts to US$3.71, while the consensus price target remained at US$45.82.
Analysts Have Made A Financial Statement On Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Second-Quarter Report
Stoke Therapeutics, Inc. (NASDAQ:STOK) saw an 8.3% share price increase after its Q2 report, with revenues of US$9.3m beating expectations. Analysts have revised their 2026 revenue forecasts upwards to US$30.2m, reflecting a 9.4% increase, but also raised loss per share estimates to US$3.71 due to growth costs. Despite increased anticipated losses, the consensus price target remains at US$45.82, suggesting analysts are balancing revenue growth against higher expenses.
FMR LLC discloses 8.5% Stoke Therapeutics (STOK) ownership in Schedule 13G/A
FMR LLC has filed an amended Schedule 13G/A, reporting a passive ownership stake of 8.5% in Stoke Therapeutics (STOK) common stock. This represents 5,313,100 shares, with FMR LLC holding sole voting power over 5,312,516 shares and sole dispositive power over all 5,313,100 shares. Abigail P. Johnson is also reported as a beneficial owner with sole dispositive power over the same number of shares.
Analysts Have Made A Financial Statement On Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Second-Quarter Report
Stoke Therapeutics (NASDAQ:STOK) saw its shares rise 8.3% after its second-quarter report, with revenues of US$9.3m exceeding expectations, though losses also increased. Analysts have since raised revenue estimates for 2026 to US$30.2m but also increased loss per share forecasts to US$3.71, indicating higher costs for growth. Despite these adjustments, the consensus price target remained at US$45.82, suggesting analysts are balancing revenue growth against rising losses.
Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
Stoke Therapeutics announced that its CEO, Ian F. Smith, and Chief Patient Officer, Jason Hoitt, will present at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The biotechnology company focuses on RNA medicine to restore protein expression, with its lead investigational drug zorevunersen in development for Dravet syndrome. A live webcast of the presentation will be available on Stoke’s investor relations website.
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $208,391.04 in Stock
Stoke Therapeutics insider Barry Ticho sold 7,176 shares of the company's stock for $208,391.04, reducing his holdings by 26%. This sale was made under a Rule 10b5-1 trading plan. The company recently reported mixed quarterly results, with revenue exceeding estimates but a wider-than-expected loss, and analysts generally maintain a "Moderate Buy" rating with an average price target of $43.
Stoke Therapeutics (STOK) CMO sells 7,176 shares under 10b5-1 plan
Stoke Therapeutics' Chief Medical Officer, Barry Ticho, sold 7,176 shares of common stock on August 3, 2026, under a Rule 10b5-1 trading plan adopted on November 19, 2025. The sales occurred in two transactions at weighted-average prices of $28.9501 and $29.4539 per share. Following these transactions, Ticho directly holds 20,422 shares of common stock.
Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
Stoke Therapeutics reported its Q2 2026 financial results, highlighting significant progress in its clinical programs. The company completed enrollment for the Phase 3 EMPEROR study of zorevunersen for Dravet syndrome, with data expected in Q3 2027, and plans to initiate a rolling U.S. NDA submission in Q1 2027. Additionally, Stoke is advancing STK-002 for Autosomal Dominant Optic Atrophy (ADOA), with initial data anticipated in H1 2027, and maintains a strong financial position of approximately $420 million, expected to fund operations through to potential U.S. commercialization of zorevunersen in early 2028.
Stoke: 'Buy' Zorevunersen NDA SCN1A DS And STK-002 Advancement (NASDAQ:STOK)
Stoke Therapeutics (STOK) maintains a "Buy" rating due to significant progress in its clinical programs. Key milestones include an expected FDA meeting in H2 2026 and a rolling NDA submission in Q1 2027 for zorevunersen in SCN1A Dravet Syndrome, with Phase 3 EMPEROR data anticipated in Q3 2027. Additionally, the advancement of STK-002 for autosomal dominant optic atrophy highlights the broader potential of its TANGO platform, supported by a strong cash position extending into early 2028.
Dimensional Fund Advisors LP Buys 162,797 Shares of Stoke Therapeutics, Inc. $STOK
Dimensional Fund Advisors LP increased its stake in Stoke Therapeutics (NASDAQ:STOK) by 19.7% in the first quarter, acquiring an additional 162,797 shares to own a total of 989,936 shares valued at $32.2 million. Other hedge funds also adjusted their positions in the company. Stoke Therapeutics reported higher-than-expected second-quarter revenue of $9.32 million but a wider loss per share of $0.93, indicating continued cash burn, while analysts maintain a "Moderate Buy" rating with a $43 price target.
Stoke Therapeutics, Inc. Stock 12‑Month Price Target Cut to $45.64, Implies 54% Upside
Analysts have lowered the average 12-month price target for Stoke Therapeutics, Inc. (STOK) stock to $45.64 from $46.87, representing a potential 54% upside based on its August 3 closing price. Despite the cut, the consensus rating from 13 analysts remains a "Buy," with forecasts ranging from $35 to $60 per share.
Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK) announced that its CEO, Ian F. Smith, and Chief Patient Officer, Jason Hoitt, will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 11:00 a.m. ET. The company, focused on RNA medicine, is developing zorevunersen, a lead investigational medicine for Dravet syndrome. A webcast of the presentation will be available on Stoke's investor relations website.
Stoke Therapeutics (STOK) Stock Climbs As Cash Burn Meets Dravet Momentum
Stoke Therapeutics' stock rose 7% despite a widened net loss in Q2 2026, driven by positive momentum in its Phase III Dravet syndrome program. The company's cash position of US$420 million is expected to fund operations into the planned launch window, addressing investor concerns about cash burn amidst clinical development progress. Analysts are assessing whether the recent stock movement aligns with their targets, balancing the strong clinical execution against financial risks.
Wedbush Adjusts Price Target on Stoke Therapeutics to $40 From $38, Maintains Outperform Rating
Wedbush has increased its price target for Stoke Therapeutics (NASDAQ: STOK) to $40 from $38, while reiterating an Outperform rating on the stock. This adjustment follows recent company news, including the Q2 2026 earnings call and updates on their Phase 3 study for Dravet Syndrome treatment. Stoke Therapeutics is a biotechnology company focused on developing RNA-based medicines to upregulate protein expression for severe diseases.
Stoke Therapeutics, Inc. Q2 2026: Revenue $9.3M, EPS $(0.93) — 10-Q Summary
Stoke Therapeutics, Inc. reported its Q2 2026 results, showing a decrease in revenue to $9.3M from $13.8M in Q2 2025, and a widened net loss of $(61.6M) with a diluted EPS of $(0.93). The company highlighted clinical progress for zorevunersen with Phase 3 trial enrollment complete and a global readout expected in Q3 2027, alongside expansion into a Phase 1 ADOA study for STK-002. Commercial readiness efforts are underway, with a pre-NDA meeting planned for H2 2026.
How Stoke Therapeutics Inc. (STOK) Affects Rotational Strategy Timing
This article analyzes Stoke Therapeutics Inc. (STOK) using AI models to provide trading strategies for different risk profiles and holding periods. It highlights divergent sentiment, support/resistance levels, and a favorable risk-reward setup for the stock. The analysis includes position trading, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis.
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Rating of "Moderate Buy" by Analysts
Stoke Therapeutics (NASDAQ:STOK) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $43.00, despite recently missing earnings per share estimates while exceeding revenue forecasts. Insider sales by two executives under pre-arranged plans have been noted, though insiders still hold 9.6% ownership. The company is developing genetic medicines, with its lead program STK-001 in clinical trials for Dravet syndrome.
Stoke Therapeutics (NASDAQ:STOK) Issues Quarterly Earnings Results, Misses Estimates By $0.13 EPS
Stoke Therapeutics reported a quarterly loss of $0.93 per share, missing analyst estimates by $0.13, despite revenue of $9.32 million exceeding expectations. The company remains unprofitable, but its shares rose by $0.70 to $29.56 following the announcement. Analysts maintain a "Moderate Buy" consensus with an average price target of $43.00, while institutional investors have increased their holdings despite recent insider share sales.
Stoke Therapeutics Q2 Earnings Call Highlights
Stoke Therapeutics' Q2 earnings call highlighted significant progress in its EMPEROR study for zorevunersen, an investigational treatment for Dravet syndrome, with enrollment completed ahead of schedule. The company anticipates a rolling U.S. NDA submission in Q1 2027 and a potential U.S. launch in early 2028. Long-term data from open-label extension studies show durable seizure reductions and cognitive improvements, while the company also advances other pipeline candidates and maintains a strong cash position to fund operations through launch.
Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings
Stoke Therapeutics, Inc. reported its Q2 2026 earnings, with an EPS of -$0.93 against an estimated -$0.78, and revenue of $9M, significantly exceeding the $5M estimate. The company maintains approximately $420 million in liquidity, funding a planned rolling NDA submission starting Q1 2027 and a 2028 launch, with its Phase 3 EMPEROR trial fully enrolled.
Stoke Therapeutics (NASDAQ: STOK) swings to H1 2026 loss as revenue falls
Stoke Therapeutics reported a significant financial downturn in H1 2026, swinging to a net loss of $111.6 million compared to a net income of $89.4 million in H1 2025, primarily due to a sharp decline in revenue from $172.4 million to $15.6 million. This revenue drop is largely attributed to the absence of the $150.8 million Biogen license revenue recognized in the prior year. Despite increased R&D and SG&A expenses, the company maintains a cash runway through early 2028, aiming for potential U.S. commercialization of zorevunersen, its lead drug for Dravet syndrome.
Stoke's Dravet trial enrolls 162; data readout anticipated Q3 2027
Stoke Therapeutics announced the completion of enrollment for its Phase 3 EMPEROR study of zorevunersen in Dravet syndrome, with 162 patients enrolled and a data readout expected in Q3 2027. The company is preparing for a rolling U.S. NDA submission to begin in Q1 2027 and reported a Q2 2026 net loss of $61.6 million. Additionally, Stoke provided updates on its STK-002 program for ADOA and highlighted a strong financial position of $420 million, projected to fund operations through to potential U.S. commercialization of zorevunersen in early 2028.
Earnings call transcript: Stoke Therapeutics posts Q2 2026 revenue beat as Dravet drug advances
Stoke Therapeutics reported a wider-than-expected Q2 2026 loss but significantly beat revenue forecasts, driven by the advancement of its Dravet syndrome drug, zorevunersen, towards a potential U.S. launch in early 2028. The company's Phase III EMPEROR study has exceeded enrollment targets with no patient discontinuations, reinforcing confidence in its clinical and regulatory pathway. Stoke aims to initiate a rolling NDA submission in Q1 2027 and leverage extensive long-term data to support a broad label and premium pricing.
Stoke Therapeutics, Inc. $STOK Shares Acquired by Janus Henderson Group PLC
Janus Henderson Group PLC increased its stake in Stoke Therapeutics (NASDAQ:STOK) by 11.2% in the first quarter, now owning over 1.6 million shares valued at approximately $52.5 million. Despite a quarterly loss, analyst sentiment remains positive with a "Moderate Buy" consensus rating and an average price target of $43, significantly above its recent trading price of $28.86. Insiders have also recently sold shares under pre-arranged trading plans, though insiders collectively own 9.6% of the company.
OMERS ADMINISTRATION Corp Invests $1.35 Million in Stoke Therapeutics, Inc. $STOK
OMERS ADMINISTRATION Corp initiated a new position in Stoke Therapeutics, Inc. (NASDAQ:STOK) during the first quarter, purchasing 41,500 shares valued at approximately $1.35 million. Other institutional investors like Baillie Gifford & Co., Hussman Strategic Advisors Inc., and Candriam S.C.A. also hold significant stakes, with Candriam S.C.A. increasing its holdings by 12.4%. Stoke Therapeutics reported a slight beat on EPS for the quarter but missed revenue estimates, and analysts have a "Moderate Buy" rating with a consensus target price of $43.00, despite some recent insider selling activity.
Stoke Therapeutics Inc (STOK) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Stoke Therapeutics Inc (STOK), indicating its current valuation score is 8.30, ranking 147 out of 384 in the Biotechnology & Medical Research industry. The company's P/E ratio is -10.31, significantly below its recent high and above its recent low. Key metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
Stoke Therapeutics (STOK) Expected to Release Earnings on Monday
Stoke Therapeutics (NASDAQ:STOK) is anticipated to release its Q2 2026 earnings before market open on Monday, August 3rd. Analysts project a loss of $0.82 per share and $4.89 million in revenue. The company's stock, currently trading around $29.20, holds a "Moderate Buy" consensus rating with an average analyst price target of $43.00, while insider selling and institutional investment adjustments have also been noted.
